Cancer Type: Malignant Hematology
Study Type: Treatment
NCT#: NCT03671018
Phase: Phase I/II
Principal Investigator: Chavez, Julio
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma
This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab in combination with polatuzumab vedotin in participants with B-cell non-Hodgkin lymphoma (NHL). It will consist of a dose finding portion and two randomized cohorts for participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).
Safety Endpoints To evaluate the safety and tolerability of mosunetuzumab plus polatuzumab vedotin in patients with R/R DLBCL or FL, including estimation of the MTD, determination of the RP2D, and characterization of DLTs Efficacy Objective To make a preliminary assessment of the anti-tumor activity of mosunetuzumab plus polatuzumab vedotin Primary Efficacy Endpoints To evaluate the efficacy of mosunetuzumab plus polatuzumab vedotin compared with polatuzumab vedotin plus bendamustine and rituximab in patients with R/R DLBCL To evaluate the efficacy of mosunetuzumab plus polatuzumab vedotin compared with physicians choice of rituximab plus chemotherapy (CHOP or CVP) or obinutuzumab plus bendamustine followed by obinutuzumab maintenance in patients with R/R FL
Chemotherapy (NOS); Immunotherapy; Therapy (NOS)
Bendamustine (); Mosunetuzumab (); Polatuzumab Vedotin (); Rituxan (rituximab); Tocilizumab (); rituximab ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday